From: Safety of an extended-release injectable moxidectin suspension formulation (ProHeart® 12) in dogs
Timing of treatment | None (Control) | Pre-Mating | Mating | Mid-gestation | Lactation |
---|---|---|---|---|---|
Pups per Litter (mean ± SD) | 4.3 ± 2.12 | 5.5 ± 1.85 | 5.0 ± 1.77 | 6.1 ± 2.34 | 6.3 ± 1.96 |
Liveborn/Total (%) | 100 | 100 | 100 | 100 | 100 |
Postnatal viabilitya (% ± SD) | 92 ± 17.68 | 97.9 ± 5.89 | 100 ± 0.00 | 93.3 ± 8.64 | 100 ± 0.00 |
Birth weight (g) (mean ± SD) | |||||
Males | 308 ± 31.6 | 300 ± 47.62 | 290 ± 50.91 | 275 ± 35.40 | 309 ± 55.46 |
Females | 292 ± 26.30 | 266 ± 72.34 | 270 ± 27.98 | 269 ± 22.29 | 295 ± 39.90 |
Weaning weight (g) (mean ± SD) | |||||
Males | 2288 ± 134.7 | 2172 ± 242.8 | 2170 ± 252.9 | 2060 ± 172.2 | 2174 ± 503.9 |
Females | 1996 ± 221.7 | 1912 ± 310.4 | 2038 ± 394.0 | 1914 ± 282.3 | 1865 ± 330.1 |